Company & Sponsor Intelligence
Johns Hopkins University
Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.
Request enterprise analysis →Indexed trials2
Recruiting2
Completed0
Countries1
Therapeutic footprint
alzheimersparkinsons
Indexed studies
NCT00681239Atkins Plus KetoCal for Childhood Epilepsy
epilepsy · United StatesPHASE3
epilepsy · United StatesPHASE3
NCT05824728Clinical Trial Evaluating the Efficacy and Safety of AGB101 for Treatment of Parkinson's Disease Related Psychosis
parkinsons · United StatesPHASE2
parkinsons · United StatesPHASE2
NCT05795634Cognitive Vulnerability to Stress in Individuals at Risk for Alzheimer's Disease
alzheimers · United StatesNA
alzheimers · United StatesNA
Intelligence layer updated: 2026-06-10 02:57:56.223123+00:00
Enterprise intelligence
Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.
Request comparative intelligence →